Gene therapy in orthopaedic surgery: The current status

ANZ Journal of Surgery

Volumn 74, Issue 1-2, 2004, Pages 46-54

  Jüllig, Mia ^a   Zhang, Wei V ^a   Stott, N Susan ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Clinical trial; Gene therapy; Vector; Virus

Indexed keywords

ADENOVIRUS VECTOR; HERPESVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

BECKER MUSCULAR DYSTROPHY; BONE DEFECT; BONE TUMOR; DUCHENNE MUSCULAR DYSTROPHY; FRACTURE; GENE TARGETING; GENE THERAPY; HEMOPHILIA; HERPES SIMPLEX VIRUS; HUMAN; MUSCLE INJURY; MUSCULAR DYSTROPHY; MUSCULOSKELETAL DISEASE; NONVIRAL GENE THERAPY; OSTEOARTHRITIS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SOFT TISSUE TUMOR; TISSUE REPAIR; TREATMENT INDICATION; VIRAL GENE THERAPY;

ANIMALS; CLINICAL PROTOCOLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUSCULOSKELETAL DISEASES; ORTHOPEDICS;

EID: 1342301584     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-1433.2003.documendoc.doc.x     Document Type: Review

References (112)

1. Culver KW, Anderson WF, Blaese RM. Lymphocyte gene therapy. Hum. Gene Ther. 1991; 2: 107-9.
2. Blaese RM. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. Pediatr. Res. 1993; 33: S49-55.
3. Lyngstadaas A. Status and potential of gene therapy in clinical medicine. Assessment of an emerging health technology through systematic survey of clinical gene therapy protocols and published results. Int. J. Technol. Assess. Health Care 2002; 18: 645-74.
4. Evans CH, Robbins PD, Ghivizzani SC et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum. Gene Ther. 1996; 7: 1261-80.
5. Evans CH, Ghivizzani SC, Oligino TA et al. Future of adenoviruses in the gene therapy of arthritis. Arthritis Res. 2001; 3: 142-6.
6. Polisson R. Innovative therapies in osteoarthritis. Curr. Rheumatol. Report 2001; 3: 489-95.
7. Baltzer AW, Whalen JD, Wooley P et al. Gene therapy for osteoporosis: evaluation in a murine ovariectomy model. Gene Ther. 2001; 8: 1770-6.
8. Baltzer AW, Lattermann C, Whalen JD et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther. 2000; 7: 734-9.
9. Goto H, Shuler FD, Lamsam C et al. Transfer of lacZ marker gene to the meniscus. J. Bone Joint Surg. Am. 1999; 81: 918-25.
10. Goater JJ, O'Keefe RJ, Rosier RN et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J. Orthop. Res. 2002; 20: 169-73.
11. Forlino A, Marini JC. Osteogenesis imperfecta: prospects for molecular therapeutics. Mol. Genet. Metab. 2000; 71: 225-32.
12. Niyibizi C, Smith P, Mi Z et al. Potential of gene therapy for treating osteogenesis imperfecta. Clin. Orthop. 2000; 379 (Suppl.): S126-33.
13. Walsh CE. Gene therapy progress and prospects: Gene therapy for the hemophilias. Gene Ther. 2003; 10: 999-1003.
14. Chamberlain JS. Gene therapy of muscular dystrophy. Hum. Mol. Genet. 2002; 11: 2355-62.
15. Acsadi G, Dickson G, Love DR et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991; 352: 815-18.
16. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 1998; 16: 867-70.
17. Audouy SA, de Leij LF, Hoekstra D et al. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm. Res. 2002; 19: 1599-605.
18. Tousignant JD, Gates AL, Ingram LA et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum. Gene Ther. 2000; 11: 2493-513.
19. Norman J, Denham W, Denham D et al. Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 2000; 7: 1425-30.
20. Li S, Wu SP, Whitmore M et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am. J. Physiol. 1999; 276: L796-804.
21. Dow SW, Fradkin LG, Liggitt DH et al. Lipid-DNA complexes induce potent activation of innate immune responses and anti-tumor activity when administered intravenously. J. Immunol. 1999; 163: 1552-61.
22. Natsume A, Mizuno M, Ryuke Y et al. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. 1999; 6: 1626-33.
23. Ghivizzani SC, Oligino TJ, Glorioso JC et al. Direct gene delivery strategies for the treatment of rheumatoid arthritis. Drug Discov. Today 2001; 6: 259-67.
24. Ghivizzani SC, Lechman ER, Kang R et al. Direct adenovirusmediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl Acad. Sci. USA 1998; 95: 4613-18.
25. Yang Y, Nunes FA, Berencsi K et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci. USA 1994; 91: 4407-11.
26. Yang Y, Li Q, Ertl HC et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 1995; 69: 2004-15.
27. Nishida K, Kang JD, Gilbertson LG et al. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine 1999; 24: 2419-25.
28. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol. Ther. 1998; 80: 35-47.
29. Hunt KK, Vorburger SA. Technical Sight. Gene therapy. Hurdles and hopes for cancer treatment. Science 2002; 297: 415-16.
30. Stedman H, Wilson JM, Finke R et al. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum. Gene Ther. 2000; 11: 777-90.
31. Goater J, Muller R, Kollias G et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J. Rheumatol 2000; 27: 983-9.
32. Arai Y, Kubo T, Fushiki S et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J. Rheumatol. 2000; 27: 979-82.
33. Madry H, Cucchiarini M, Terwilliger EF et al. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum. Gene Ther. 2003; 14: 393-402.
34. Snyder RO, Miao CH, Patijn GA et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 1997; 16: 270-6.
35. Kessler PD, Podsakoff GM, Chen X et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl Acad. Sci. USA 1996; 93: 14082-7.
36. Kaplitt MG, Leone P, Samulski RJ et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 1994; 8: 148-54.
37. Herzog RW, Hagstrom JN, Kung SH et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl Acad. Sci. USA 1997; 94: 5804-9.
38. High K. AAV-mediated gene transfer for hemophilia. Genet. Med. 2002; 4: 56S-61S.
39. Aitken ML, Moss RB, Waltz DA et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 2001; 12: 1907-16.
40. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002; 9: 967-78.
41. Glorioso JC, Goins WF, Fink DJ et al. Herpes simplex virus vectors and gene transfer to brain. Dev. Biol. Stand. 1994; 82: 79-87.
42. Oligino T, Ghivizzani S, Wolfe D et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther. 1999; 6: 1713-20.
43. Bowers WJ, Olschowka JA, Federoff HJ. Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther. 2003; 10: 941-5.
44. Olschowka JA, Bowers WJ, Hurley SD et al. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol. Ther. 2003; 7: 218-27.
45. Hacein-Bey-Abina S, Le Deist F, Carlier F et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 2002; 346: 1185-93.
46. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003; 299: 320.
47. Kaiser J. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science 2003; 299: 495.
48. Marshall E. Gene therapy. What to do when clear success comes with an unclear risk? Science 2002; 298: 510-11.
49. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003; 348: 255-6.
50. Kaiser J. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk. Science 2003; 299: 991.
51. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-5.
52. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther. 2002; 9: 979-86.
53. Harvey BG, Maroni J, O'Donoghue KA et al. Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 2002; 13: 15-63.
54. Crystal RG, Harvey BG, Wisnivesky JP et al. Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 2002; 13: 65-100.
55. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther. 2003; 10: 902-11.
56. Eastgate JA, Symons JA, Wood NC et al. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 706-9.
57. Rooney M, Symons JA, Duff GW. Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol. Int. 1990; 10: 217-19.
58. Kahle P, Saal JG, Schaudt K et al. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann. Rheum. Dis. 1992; 51: 731-4.
59. Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-40.
60. Arend WP, Malyak M, Guthridge CJ et al. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 1998; 16: 27-55.
61. Horai R, Saijo S, Tanioka H et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 2000; 191: 313-20.
62. Bessis N, Doucet C, Cottard V et al. Gene therapy for rheumatoid arthritis. J. Gene Med. 2002; 4: 581-91.
63. Whalen JD, Lechman EL, Carlos CA et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J. Immunol. 1999; 162: 3625-32.
64. Hung GL, Galea-Lauri J, Mueller GM et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther. 1994; 1: 64-9.
65. Goomer RS, Maris TM, Gelberman R et al. Nonviral in vivo gene therapy for tissue engineering of articular cartilage and tendon repair. Clin. Orthop. 2000; 379 (Suppl.): S189-200.
66. Goto H, Shuler FD, Niyibizi C et al. Gene therapy for meniscal injury: enhanced synthesis of proteoglycan and collagen by meniscal cells transduced with a TGFbeta (1) gene. Osteoarthritis Cartilage 2000; 8: 266-71.
67. Fewell JG, Nordstrom JL. Regulated production of proteins from muscle using gene transfer: potential therapeutic applications. Expert Opin. Biol. Ther. 2003; 3: 277-91.
68. Lou J, Tu Y, Burns M et al. BMP-12 gene transfer augmentation of lacerated tendon repair. J. Orthop. Res. 2001; 19: 1199-202.
69. Martinek V, Latterman C, Usas A et al. Enhancement of tendon-bone integration of anterior cruciate ligament grafts with bone morphogenetic protein-2 gene transfer: a histological and biomechanical study. J. Bone Joint Surg. Am. 2002; 84: 1123-31.
70. Moutsatsos IK, Turgeman G, Zhou S et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol. Ther. 2001; 3: 449-61.
71. Hayda RA, Brighton CT, Esterhai JL Jr. Pathophysiology of delayed healing. Clin. Orthop. 1998; 355 (Suppl.): S31-40.
72. Kubler N, Urist MR. Allogenic bone and cartilage morphogenesis. Rat BMP in vivo and in vitro. J. Craniomaxillofac. Surg. 1991; 19: 283-8.
73. Okubo Y, Bessho K, Fujimura K et al. Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites. Int. J. Oral Maxillofac. Surg. 2000; 29: 62-6.
74. Aspenberg P, Turek T. BMP-2 for intramuscular bone induction: effect in squirrel monkeys is dependent on implantation site. Acta Orthop. Scand. 1996; 67: 3-6.
75. Rutherford RB, Moalli M, Franceschi RT et al. Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng. 2002; 8: 441-52.
76. Musgrave DS, Pruchnic R, Bosch P et al. Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. J. Bone Joint Surg. Br. 2002; 84: 120-7.
77. Gysin R, Wergedal JE, Sheng MH et al. Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats. Gene Ther. 2002; 9: 991-9.
78. Gelse K, Jiang QJ, Aigner T et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum. 2001; 44: 1943-53.
79. Lieberman JR, Ghivizzani SC, Evans CH. Gene transfer approaches to the healing of bone and cartilage. Mol. Ther. 2002; 6: 141-7.
80. Madry H, Zurakowski D, Trippel SB. Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. Gene Ther. 2001; 8: 1443-9.
81. Kang R, Marui T, Ghivizzani SC et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarth. Cart. 1997; 5: 139-43.
82. Clayman GL, el-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 1998; 16: 2221-32.
83. Schuler M, Herrmann R, De Greve JL et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J. Clin. Oncol. 2001; 19: 1750-8.
84. Tsuchiya H, Mori Y, Ueda Y et al. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res. 2000; 20: 235-42.
85. Skotzko M, Wu L, Anderson WF et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 1995; 55: 5493-8.
86. Densmore CL, Kleinerman ES, Gautam A et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 2001; 8: 619-27.
87. Seto M, Yamazaki T, Sonoda J et al. Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy. Oncol. Report 2002; 9: 337-40.
88. Seto M, Wakabayashi H, Yamazaki T et al. Gene therapy of chondrosarcoma using retrovirus vectors encoding the herpes simplex virus thymidine kinase gene. Int. J. Oncol. 1999; 14: 1137-41.
89. Witlox MA, Van Beusechem VW, Grill J et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med. 2002; 4: 510-16.
90. Rainov NG. A phase in clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 2000; 11: 2389-401.
91. Izquierdo M, Cortes M, de Felipe P et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther. 1995; 2: 66-9.
92. Kirn D, Martuza RL, Zwiebel J. Replication-selective viro-therapy for cancer. Biological principles, risk management and future directions. Nat. Med. 2001; 7: 781-7.
93. Benjamin R, Helman L, Meyers P et al. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum. Gene Ther. 2001; 12: 1591-3.
94. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-28.
95. Petrof BJ, Shrager JB, Stedman HH et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 1993; 90: 3710-14.
96. Bulfield G, Siller WG, Wight PA et al. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA 1984; 81: 1189-92.
97. Wells DJ, Wells KE. Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD? Neuromuscul. Disord. 2002; 12: S11-22.
98. DelloRusso C, Scott JM, Hartigan-O'Connor D et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl Acad. Sci. USA 2002; 99: 12979-84.
99. Romero NB, Benveniste O, Payan C et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol. Neuromuscul. Disord. 2002; 12: S45-8.
100. Thioudellet C, Blot S, Squiban P et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale. Neuromuscul. Disord. 2002; 12: S49-51.
101. Zhang G, Budker V, Williams P et al. Efficient expression of naked dna delivered intraarterially to limb muscles of non-human primates. Hum. Gene Ther. 2001; 12: 427-38.
102. Arruda VR, Hagstrom JN, Deitch J et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130-8.
103. Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin. Hematol. 1998; 35: 11-17.
104. Herzog RW, Yang EY, Couto LB et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 1999; 5: 56-63.
105. Kay MA, Manno CS, Ragni MV et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 2000; 24: 257-61.
106. Manno CS, Chew AJ, Hutchison S et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101; 2963-72.
107. Herzog RW, Fields PA, Arruda VR et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 2002; 13: 1281-91.
108. Mount JD, Herzog RW, Tillson DM et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-6.
109. Millington-Ward S, Allers C, Tuohy G et al. Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta. Hum. Mol. Genet. 2002; 11: 2201-6.
110. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplant-ability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999; 5: 309-13.
111. Niyibizi C, Wallach CJ, Mi Z et al. Approaches for skeletal gene therapy. Crit. Rev. Eukaryot. Gene Expr. 2002; 12: 163-73.
112. Bunch WH, Drennan JC. The ethics of the introduction of gene therapy into orthopaedic practice. Clin. Orthop. 2000; 379 (Suppl.): S59-64.